A nicely worded news release. It would have been nice for them to better highlight the outstanding %RRR in the CKD subgroup and in those on SGLT2 inhibitor or GLP1R agonists. Too late now, but they could have linked to their previous news releases on these topics, or to their excellent post AHA corporate presentation. Would have also been nice to hear mention of the cognition and CKD sub-studies (renal function) too.

BDAZ